Claims

1. Use of an ophthalmic composition in the manufacture of a medicament for treatment of severity of dryness in a patient suffering from dry eye disease associated with Meibomian Gland Dysfunction, wherein the composition essentially consists of 1-perfluorohexyloctane, and wherein the composition is to be topically administered for up to 4 times daily as a single drop of 10-12 µl to the eye of a patient, and wherein the patient is characterized by a MGD score of equal or higher than 7.

2. Use of an ophthalmic composition in the manufacture of a medicament for treatment of ocular surface damage of the central corneal region, in a patient suffering from dry eye disease associated with Meibomian Gland Dysfunction, wherein the composition essentially consists of 1-perfluorohexyloctane, and wherein the composition is to be topically administered for up to 4 times daily as a single drop of 10-12 µl to the eye of a patient, and wherein the patient is characterized by a MGD score of equal or higher than 7.

3. Use of an ophthalmic composition in the manufacture of a medicament for treatment of ocular surface damage of the central corneal region and for the treatment of severity of dryness in a patient suffering from dry eye disease associated with Meibomian Gland Dysfunction, wherein the composition essentially consists of 1-perfluorohexyloctane, and wherein the composition is to be topically administered for up to 4 times daily as a single drop of 10-12 µl to the eye of a patient, and wherein the patient is characterized by a MGD score of equal or higher than 7.

4. The use according to any preceding claim, wherein the patient to be treated is further characterized by one or more criteria selected from :
   i. a tear film breakup time (TBUT) of lower than 3 sec,
   ii. an ocular surface disease index (OSDI) of higher than 57,

iii. a total corneal fluorescein staining (NEI scale) between 5 and 9.

5. The use according to any preceding claim, wherein the composition is to be administered as a single drop of about 11 µl to the eye of a patient.

6. The use according to any preceding claim, wherein the composition is further effective in treating (reducing) the ocular surface damage of the total corneal region and/or the nasal corneal region and/or the temporal corneal region and/or the inferior corneal region.

7. The use according to any preceding claim, wherein the composition is further effective in treating (reducing) the frequency of dryness and/or the awareness of dryness and/or the burning/stinging and/or the itching and/or the sticky feeling and/or the blurred vision and/or the foreign body sensation and/or the total ocular surface disease index (OSDI) score.

8. The use according any of the preceding claims, wherein the patient is suffering from evaporative keratoconjunctivitis sicca (dry eye disease) associated with Meibomian gland dysfunction.

9. The use according any of the preceding claims, wherein the patient is not responsive to treatment with artificial tears.

10. The use according to any of the preceding claims, wherein the patient is a female.

11. The use according to according any of the preceding claims, wherein the ocular surface damage of the corneal region is determined by grading the central corneal region by fluorescein staining of the cornea.

12. The use according to according any of the preceding claims, wherein the severity of dryness, the burning/stinging, the itching feeling, the sticky feeling, the blurred vision and/or the foreign body sensation are determined by the Eye Dryness Score on a visual analog scale (VAS) from 0% to 100% indicating the level of discomfort

of the patient and wherein the reduction of frequency of dryness and/or the awareness of dryness is determined by the Eye Dryness Score on a visual analog scale (VAS) from 0% to 100% indicating the percentage of time said dryness symptoms are experienced by the patient, and wherein the total ocular surface disease index (OSDI) score is determined on a scale of 1 to 100 with higher scores representing greater disability of the patient.